Trial Profile
A cohort study in patients with StageIIIB/IVnon-small cell lung cancer, who had treated as 1st-line Conbination therapy of Carboplatin/Paclitaxel/Bavacizumab, and 2nd-line by Erlotinib
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 21 Feb 2018
Price :
$35
*
At a glance
- Drugs Erlotinib (Primary) ; Bevacizumab; Carboplatin; Paclitaxel
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 19 Feb 2018 Status changed from recruiting to discontinued.
- 03 Aug 2011 New trial record